Date: 2017-03-30
Type of information: Collaboration agreement
Compound: predictive biomarkers such as Tumor Mutational Burden (TMB) and Microsatellite Instability (MSI)
Company: BMS (USA - NY) Foundation Medicine (USA - MA)
Therapeutic area: Cancer - Oncology
Type agreement: collaboration
Action mechanism: biomarker
Disease:
Details:
- • On March 30, 2017, BMS and Foundation Medicine announced a collaboration that leverages Foundation Medicine’s comprehensive genomic profiling and molecular information solutions to identify predictive biomarkers such as Tumor Mutational Burden (TMB) and Microsatellite Instability (MSI) in patients enrolled across clinical trials investigating BMS' cancer immunotherapies. Foundation Medicine’s approach utilizing its FoundationOne® assay combines comprehensive genomic profiling with its advanced and proprietary algorithms to measure biomarkers, including TMB and MSI, without the need for whole exome sequencing.
Financial terms:
Latest news:
Is general: Yes
